» Articles » PMID: 11830668

Targeting the Prostate for Destruction Through a Vascular Address

Overview
Specialty Science
Date 2002 Feb 7
PMID 11830668
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Organ specific drug targeting was explored in mice as a possible alternative to surgery to treat prostate diseases. Peptides that specifically recognize the vasculature in the prostate were identified from phage-displayed peptide libraries by selecting for phage capable of homing into the prostate after an i.v. injection. One of the phage selected in this manner homed to the prostate 10-15 times more than to other organs. Unselected phage did not show this preference. The phage bound also to vasculature in the human prostate. The peptide displayed by the prostate-homing phage, SMSIARL (single letter code), was synthesized and shown to inhibit the homing of the phage when co-injected into mice with the phage. Systemic treatment of mice with a chimeric peptide consisting of the SMSIARL homing peptide, linked to a proapoptotic peptide that disrupts mitochondrial membranes, caused tissue destruction in the prostate, but not in other organs. The chimeric peptide delayed the development of the cancers in prostate cancer-prone transgenic mice (TRAMP mice). These results suggest that it may be possible to develop an alternative to surgical prostate resection and that such a treatment may also reduce future cancer risk.

Citing Articles

Biological Activity of Natural and Synthetic Peptides as Anticancer Agents.

Bauso L, La Fauci V, Munao S, Bonfiglio D, Armeli A, Maimone N Int J Mol Sci. 2024; 25(13).

PMID: 39000371 PMC: 11242495. DOI: 10.3390/ijms25137264.


Peptides as multifunctional players in cancer therapy.

Vadevoo S, Gurung S, Lee H, Gunassekaran G, Lee S, Yoon J Exp Mol Med. 2023; 55(6):1099-1109.

PMID: 37258584 PMC: 10318096. DOI: 10.1038/s12276-023-01016-x.


Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties.

Andre A, Moutinho I, Dias J, Aires-da-Silva F Front Microbiol. 2022; 13:962124.

PMID: 36225354 PMC: 9549074. DOI: 10.3389/fmicb.2022.962124.


Deciphering endothelial heterogeneity in health and disease at single-cell resolution: progress and perspectives.

Becker L, Chen S, Rodor J, de Rooij L, Baker A, Carmeliet P Cardiovasc Res. 2022; 119(1):6-27.

PMID: 35179567 PMC: 10022871. DOI: 10.1093/cvr/cvac018.


Anti-angiogenic peptides application in cancer therapy; a review.

Shoari A, Khodabakhsh F, Cohan R, Salimian M, Karami E Res Pharm Sci. 2021; 16(6):559-574.

PMID: 34760005 PMC: 8562409. DOI: 10.4103/1735-5362.327503.


References
1.
Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A . Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000; 18(11):1185-90. DOI: 10.1038/81183. View

2.
Smith G, Scott J . Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 1993; 217:228-57. DOI: 10.1016/0076-6879(93)17065-d. View

3.
Koivunen E, Wang B, Dickinson C, Ruoslahti E . Peptides in cell adhesion research. Methods Enzymol. 1994; 245:346-69. DOI: 10.1016/0076-6879(94)45019-6. View

4.
Pasqualini R, Ruoslahti E . Organ targeting in vivo using phage display peptide libraries. Nature. 1996; 380(6572):364-6. DOI: 10.1038/380364a0. View

5.
Javadpour M, Juban M, Lo W, Bishop S, Alberty J, Cowell S . De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem. 1996; 39(16):3107-13. DOI: 10.1021/jm9509410. View